Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer
Checked against the public recordLast updated May 2, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Interventions being studied
- Drug: Premetrexed (Alimta); Drug: Carboplatin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Unresectable Stage II, IIIB or IV non small cell lung cancer. Evaluable disease on planning CT scan Zubrod 0-1 Weight loss equal to or less than 10% 3 months prior to diagnosis FEV1 greater than 1000cc Adequate hematologic, renal and hepatic functions Exclusion Criteria: * Small cell cancer Stage I non small cell cancer Prior chemotherapy or thoracic or lower neck radiatio therapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 2, 2025. Always confirm current availability with the study team.